Brief: Lumos Pharma Completes Patient Enrollment In Two Phase 2 Oragrowth Trials Evaluating Oral Lum-201 In Moderate Idiopathic Pghd
28/02/2023 22:35
Feb 28 (Reuters) - Lumos Pharma Inc LUMO.O :
* LUMOS PHARMA COMPLETES PATIENT ENROLLMENT IN TWO PHASE 2
ORAGROWTH TRIALS EVALUATING ORAL LUM-201 IN MODERATE IDIOPATHIC
PGHD
Source text for Eikon: ID:nGNX2JFwCW
Further company coverage: LUMO.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Lumos Pharma
See all newsLumos Pharma Inc expected to post a loss of 76 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Apple, Hershey, Dow
U.S. STOCKS ON THE MOVE-Magnite, Nvidia, Tesla
Lumos Pharma climbs on $38 mln go-private deal
Brief: Lumos Pharma Enters Into Definitive Merger Agreement With Double Point Ventures To Go Private Via A Tender Offer Of $4.25 Cash Per Share Plus Contingent Value Rights (Cvr)